Literature DB >> 9591746

Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways.

F B Kraemer1, D Takeda, V Natu, C Sztalryd.   

Abstract

Lipoprotein lipase (LPL) hydrolyzes the triacylglycerol component of circulating lipoprotein particles, mediating the uptake of fatty acids into adipose tissue and muscle. Insulin is the principal factor responsible for regulating LPL activity in adipose tissue, yet the mechanisms whereby insulin controls LPL expression are unknown. The current studies used wortmannin, a specific inhibitor of phosphatidylinositol (PI) 3-kinase, and rapamycin, a specific inhibitor of activation of phosphoprotein 70 ribosomal protein S6 kinase (p70s6k), to explore some of the components of the insulin signaling pathway controlling LPL activity in adipose cells. Preincubation of isolated rat adipose cells with wortmannin completely abrogated the stimulation of LPL activity by insulin, while preincubation with rapamycin caused approximately a 60% inhibition of insulin-stimulated LPL activity. Thus, the current studies show that the regulation of adipose tissue LPL by insulin is mediated via a wortmannin-sensitive pathway, most likely PI 3-kinase, and that a rapamycin-sensitive pathway, most likely p705s6k, constitutes an important downstream component in the insulin signaling pathway through which LPL is regulated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591746     DOI: 10.1016/s0026-0495(98)90239-6

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  13 in total

1.  Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.

Authors:  Naifa L Busaidy; Azeez Farooki; Afshin Dowlati; John P Perentesis; Janet E Dancey; Laurence A Doyle; Joanna M Brell; Lillian L Siu
Journal:  J Clin Oncol       Date:  2012-07-09       Impact factor: 44.544

2.  Insulin and dexamethasone stimulation of cardiac lipoprotein lipase activity involves the actin-based cytoskeleton.

Authors:  H S Ewart; D L Severson
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

3.  Mechanistic Target of Rapamycin (mTOR) Inhibitors.

Authors:  Denise Wang; Howard J Eisen
Journal:  Handb Exp Pharmacol       Date:  2022

Review 4.  Cardiometabolic Consequences of Targeted Anticancer Therapies.

Authors:  Avirup Guha; Yan Gong; David DeRemer; Jocelyn Owusu-Guha; Susan F Dent; Richard K Cheng; Neal L Weintraub; Neeraj Agarwal; Michael G Fradley
Journal:  J Cardiovasc Pharmacol       Date:  2022-10-01       Impact factor: 3.271

Review 5.  Insulin signalling mechanisms for triacylglycerol storage.

Authors:  M P Czech; M Tencerova; D J Pedersen; M Aouadi
Journal:  Diabetologia       Date:  2013-02-27       Impact factor: 10.122

Review 6.  The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.

Authors:  Kamalesh Sankhala; Alain Mita; Kevin Kelly; Devalingam Mahalingam; Francis Giles; Monica Mita
Journal:  Target Oncol       Date:  2009-04-21       Impact factor: 4.493

7.  Characterization of lipoprotein lipase storage vesicles in 3T3-L1 adipocytes.

Authors:  Benjamin S Roberts; Chelsea Q Yang; Saskia B Neher
Journal:  J Cell Sci       Date:  2021-08-12       Impact factor: 5.235

8.  The interferon-gamma-mediated inhibition of lipoprotein lipase gene transcription in macrophages involves casein kinase 2- and phosphoinositide-3-kinase-mediated regulation of transcription factors Sp1 and Sp3.

Authors:  Sandra M Harris; Elizabeth J Harvey; Timothy R Hughes; Dipak P Ramji
Journal:  Cell Signal       Date:  2008-08-28       Impact factor: 4.315

Review 9.  The role of fatty acids in insulin resistance.

Authors:  Barry Sears; Mary Perry
Journal:  Lipids Health Dis       Date:  2015-09-29       Impact factor: 3.876

Review 10.  Targeting the PI3K-AKT-mTOR signaling network in cancer.

Authors:  Khurum H Khan; Timothy A Yap; Li Yan; David Cunningham
Journal:  Chin J Cancer       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.